Gregory F Okasinski

Title: Gregory F. Okasinski: Innovator in Hepatitis C Research

Introduction

Gregory F. Okasinski is a notable inventor based in Wadsworth, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of expression systems for hepatitis C virus proteins. With a total of 3 patents, his work has the potential to advance medical research and treatment options for hepatitis C.

Latest Patents

One of Gregory's latest patents is focused on a novel mammalian expression system for the hepatitis C virus second envelope (HCV-E2) glycoprotein. This invention addresses the challenges of generating high levels of expressed HCV proteins, which have been difficult to express due to their non-secretory properties. The patent describes a plasmid designated p577, which encodes a recombinant protein that includes the immunoglobulin signal peptide and amino acids 388-664 of the HCV E2 glycoprotein. This unique expression system is capable of producing high levels of properly processed, glycosylated, and folded HCV proteins.

Career Highlights

Gregory F. Okasinski is associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His work at Abbott has allowed him to focus on innovative solutions in the field of biotechnology, particularly in relation to viral proteins and their applications in medicine.

Collaborations

Throughout his career, Gregory has collaborated with esteemed colleagues such as Verlyn G. Schaefer and Peter J. DeVries. These collaborations have contributed to the advancement of research and development in the field of hepatitis C.

Conclusion

Gregory F. Okasinski's contributions to the field of biotechnology, particularly through his patents related to hepatitis C virus proteins, highlight his role as an innovator in medical research. His work continues to pave the way for advancements in treatment options for hepatitis C.